Clinical research (ALS) using autologous fat tissue from the mesenchymal stem cells
- Conditions
- Amyotrophic lateral sclerosis
- Registration Number
- JPRN-UMIN000024132
- Lead Sponsor
- Medical corporation foundation Kouseikai Takeda Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 6
Not provided
The patient corresponding to the following standards excludes it from a patient targeted for the final examination. 1 The person that quantity of fat necessary for this study is not provided 2 The patient whom I am dialyzing 3 Pregnant patient 4 This study medical attendant is the patient who ethical, it is scientific, and made a decision from the viewpoint of safety if the participation in this study is inappropriate of the subject 5 The patient who needs Agent approval I confirm an anamnesis to advocate next and, from having experience or not that underwent a blood transfusion or transplant, do a competent thing judging. But I decide to reconfirm when I become able to confirm it about the anamnesis which I was not able to confirm at the time of a competent judgment later. 1 Infection with bacteria such as Treponema pallidum, a gonococcus, the tubercle bacillus 2 Sepsis and the doubt 3 Malignant tumor 4 Serious metabolism internal secretion disease 5 Serious blood disorder 6 Liver disease 7 Communicable spongy brain fever and the doubt 8 Family career to be concerned with a specific hereditary disease and the disease concerned 9 Pulmonary embolism
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method I perform the evaluation by an examination for physical views and living body, a laboratory determination. I do not compare the administrated group, the non-administrated group like a clinical trial, and this study medical attendant and neurology medical attendant evaluate a symptom change at a symptom improvement degree in equivalence people over time in comparison with in front of stem cell dosage. I am based on before dosage and evaluate the change of various kinds of symptoms (including dysphagia, an articulation disorder, muscle weakness).
- Secondary Outcome Measures
Name Time Method